Important: The starting dose (2.5 mg) is for starting the treatment only and is not used for glycemic control
You will be supplied with a 4-week supply of Semaglutide GLP-1, syringes, and sharps container
Supplementing with this substance could lead to results related to lessening wrinkles and increasing skin elasticity, as well as improved brain function
Geniposide, acting as a GLP-1R agonist, partially prevented STZ-induced learning and memory impairment via modulation of PI3K/GSK-3 signaling pathway and reduced STZ-induced hyperphosphorylation of tau protein (220)
Results May Vary Individual results will vary based on factors including age, baseline weight, metabolic health, consistency of medication use, lifestyle factors (diet, physical activity, sleep), genetic factors, current medications, and other individual variables